These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35512098)

  • 21. SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas.
    Mori T; Sukeda A; Sekine S; Shibata S; Ryo E; Okano H; Suzuki S; Hiraoka N
    Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5445-5451. PubMed ID: 29059311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
    Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG
    Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chloroquine Sensitizes
    Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
    Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Driver mutations in
    García-Mulero S; Fornelino R; Punta M; Lise S; Varela M; Del Carpio LP; Moreno R; Costa-García M; Rieder D; Trajanoski Z; Gros A; Alemany R; Piulats JM; Sanz-Pamplona R
    Oncoimmunology; 2023; 12(1):2261278. PubMed ID: 38126027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
    Ambrosini G; Sawle AD; Musi E; Schwartz GK
    Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish.
    Mouti MA; Dee C; Coupland SE; Hurlstone AF
    Oncotarget; 2016 Jun; 7(26):39654-39670. PubMed ID: 27166257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan.
    Ominato J; Fukuchi T; Sato A; Yamaguchi N; Kobayashi K; Cho H; Oyama T; Ajioka Y
    Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):658-663. PubMed ID: 28248732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma.
    Zhang Y; Zhang B; Li Y; Dai Y; Li J; Li D; Xia Z; Zhang J; Liu P; Chen M; Jiao B; Ren R
    Front Med; 2022 Oct; 16(5):784-798. PubMed ID: 35997986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
    Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
    Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In uveal melanoma Gα-protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than Gα-protein GNAQ mutations.
    Piaggio F; Croce M; Reggiani F; Monti P; Bernardi C; Ambrosio M; Banelli B; Dogrusöz M; Jockers R; Bordo D; Puzone R; Viaggi S; Coviello D; Lanza FB; Bartolucci M; Petretto A; Mosci C; Gangemi R; van der Velden PA; Jager MJ; Pfeffer U; Amaro A
    Eur J Cancer; 2022 Jul; 170():27-41. PubMed ID: 35580369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.
    Arang N; Lubrano S; Ceribelli M; Rigiracciolo DC; Saddawi-Konefka R; Faraji F; Ramirez SI; Kim D; Tosto FA; Stevenson E; Zhou Y; Wang Z; Bogomolovas J; Molinolo AA; Swaney DL; Krogan NJ; Yang J; Coma S; Pachter JA; Aplin AE; Alessi DR; Thomas CJ; Gutkind JS
    Cell Rep Med; 2023 Nov; 4(11):101244. PubMed ID: 37858338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic mutations in GNAQ occur early in uveal melanoma.
    Onken MD; Worley LA; Long MD; Duan S; Council ML; Bowcock AM; Harbour JW
    Invest Ophthalmol Vis Sci; 2008 Dec; 49(12):5230-4. PubMed ID: 18719078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MITF in Normal Melanocytes, Cutaneous and Uveal Melanoma: A Delicate Balance.
    Gelmi MC; Houtzagers LE; Strub T; Krossa I; Jager MJ
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese.
    Xu X; Wei WB; Li B; Gao F; Zhang Z; Jonas JB
    PLoS One; 2014; 9(10):e109699. PubMed ID: 25280020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
    Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
    Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
    Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
    Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
    Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
    Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of GNAQ germline mutations in uveal melanoma patients with high risk for hereditary cancer predisposition.
    Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BB; Davidorf FH
    Fam Cancer; 2011 Jun; 10(2):319-21. PubMed ID: 21072599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic Profiling of Metastatic Uveal Melanoma Shows Frequent Coexisting BAP1 or SF3B1 and GNAQ/GNA11 Mutations and Correlation With Prognosis.
    Isaacson AL; Sompallae RR; Guseva NV; Bellizzi AM; Bossler AD; Ma D
    Am J Clin Pathol; 2022 Aug; 158(2):177-186. PubMed ID: 35212356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
    Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
    J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.